紫杉醇脂质体与传统紫杉醇治疗卵巢癌的疗效及不良反应分析

发布时间：2018-01-16 03:37

本文关键词：紫杉醇脂质体与传统紫杉醇治疗卵巢癌的疗效及不良反应分析　出处：《泰山医学院》2014年硕士论文　论文类型：学位论文

【摘要】：研究目的对紫杉醇脂质体联合卡铂和传统紫杉醇联合卡铂两种化疗方案治疗卵巢癌的疗效及不良反应进行分析，评价两方案的利弊，寻求更优化的卵巢癌化疗方案。研究方法收集2012.6-2013.12在本院治疗的卵巢癌患者65例。所有患者均接受过卵巢肿瘤细胞减灭术，，术后病理确诊为原发性上皮性卵巢癌。将患者分为观察组和对照组，观察组（30例）予以紫杉醇脂质体（力朴素）（135～175mg/m2）联合卡铂方案化疗，对照组（35例）予以传统用紫杉醇（135～175mg/m2）联合卡铂方案化疗，每3周为1个周期，共6个周期。研究结果紫杉醇脂质体联合卡铂与紫杉醇联合卡铂两种化疗方案比较在卵巢癌总体有效率方面两组差异无统计学意义（P=0.324）；但是两者在某些化疗不良反应方面差异有统计学意义。紫杉醇脂质体联合卡铂在降低肌肉关节痛（P=0.013）、周围神经毒性（P=0.023）、呼吸困难（P=0.022）、恶心/呕吐（P=0.007）、面部潮红（P=0.029）及皮疹（P=0.021）、脱发（P=0.020）等不良反应的发生率明显少于紫杉醇联合卡铂。但在腹泻、腹痛及血液系统等不良反应方面，两组的差异无统计学意义。研究结论现有的临床证据显示，紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗卵巢癌疗效相当，且相对安全。因此，紫杉醇脂质体联合卡铂化疗方案可以作为治疗卵巢癌的一种新的、安全、有效的方法。由于本次研究的样本量较小，上述结论尚需大样本的随机双盲对照试验进一步证实。
[Abstract]:research objective
The efficacy and side effects of two chemotherapy regimens of paclitaxel liposome combined with carboplatin and traditional paclitaxel combined with carboplatin were analyzed. The pros and cons of the two program were evaluated, and a more optimized chemotherapy plan for ovarian cancer was sought.
research method
Collect 2012.6-2013.12 in 65 cases of patients with ovarian cancer. All patients received the ovarian cytoreductive surgery, postoperative pathology confirmed the diagnosis of primary epithelial ovarian cancer. The patients were divided into observation group and control group, the observation group (30 cases) of paclitaxel liposome (Li Pu (Su) 135 ~ 175mg/m2) and carboplatin chemotherapy, the control group (35 cases) treated by traditional paclitaxel (135 ~ 175mg/m2) and carboplatin, every 3 weeks for 1 cycles, 6 cycles.
Research results
Two kinds of chemotherapy of paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin in ovarian cancer overall efficiency difference between the two groups was not statistically significant (P=0.324); but the two in some adverse reactions in chemotherapy. There was a significant difference of paclitaxel liposome combined with platinum card in reducing muscle and joint pain (P=0.013), peripheral neurotoxicity (P=0.023) (P=0.022), dyspnea, nausea / vomiting (P=0.007), facial flushing (P=0.029) and skin rash (P=0.021), alopecia (P=0.020) and other adverse reactions were significantly less than paclitaxel combined with carboplatin. But in diarrhea, abdominal pain and adverse reactions of blood system, no statistically significant difference between the two group.
research conclusion
Current clinical evidence shows that a paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin is effective in the treatment of ovarian cancer, and relatively safe. Therefore, paclitaxel liposome combined with chemotherapy can be used as a new, safe and effective for the treatment of ovarian cancer, the method in this study. The sample size is small, this conclusion still needs a large sample randomized double-blind controlled trial further confirmed.

【学位授予单位】：泰山医学院
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【参考文献】